Recent advances in understanding preeclampsia and fetal growth restriction have elucidated important biological roles for placentally derived angiogenic factors. 5 In normal pregnancy, placental growth factor (PlGF), synthesized by syncytiotrophoblast, 6 increases with gestation in maternal circulation, with concentrations peaking at 26 to 30 weeks 7 and declining toward term. PlGF is abnormally low in women with preeclampsia in comparison with gestational agematched controls 8 and is reduced further in severe preeclampsia. 9 Development of a test for preeclampsia with the use of a pathophysiologically relevant biomarker, such as PlGF, may Background-Hypertensive disorders of pregnancy are a major contributor to death and disability for pregnant women and their infants. The diagnosis of preeclampsia by using blood pressure and proteinuria is of limited use because they are tertiary, downstream features of the disease. Placental growth factor (PlGF) is an angiogenic factor, a secondary marker of associated placental dysfunction in preeclampsia, with known low plasma concentrations in the disease. Methods and Results-In a prospective multicenter study, we studied the diagnostic accuracy of low plasma PlGF concentration (<5th centile for gestation, Alere Triage assay) in women presenting with suspected preeclampsia between 20 and 35 weeks' gestation (and up to 41 weeks' gestation as a secondary analysis). The outcome was delivery for confirmed preeclampsia within 14 days. Of 625 women, 346 (55%) developed confirmed preeclampsia. In 287 women enrolled before 35 weeks' gestation, PlGF <5th centile had high sensitivity (0.96; 95% confidence interval, 0.89-0.99) and negative predictive value (0.98; 0.93-0.995) for preeclampsia within 14 days; specificity was lower (0.55; 0.48-0.61). Area under the receiver operating characteristic curve for low PlGF (0.87, standard error 0.03) for predicting preeclampsia within 14 days was greater than all other commonly used tests, singly or in combination (range, 0.58-0.76), in women presenting with suspected preeclampsia (P<0.001 for all comparisons). Conclusions-In women presenting before 35 weeks' gestation with suspected preeclampsia, low PlGF has high sensitivity and negative predictive value for preeclampsia within 14 days, is better than other currently used tests, and presents an innovative adjunct to management of such women. (Circulation. 2013;128:2121-2131.)
P reeclampsia complicates 2% to 8% of all pregnancies and is characterized by placental and maternal vascular dysfunction and associated adverse outcomes. 1 Diagnosis is based on traditional but unreliable and nonspecific clinical markers, most commonly blood pressure and urinary protein excretion; both are subject to observer error and poor test accuracy for identifying women and infants at risk of adverse outcome. 2 This clinical uncertainty leads to overuse of ancillary testing and intervention, with associated expense of antenatal monitoring and inpatient admissions, placing considerable burden on pregnant women and their families. In the United States, preeclampsia is the most common reason for iatrogenic preterm delivery. 3 Evaluation of biomarkers and imaging techniques has shown that none have adequate sensitivity, specificity, and convenience for diagnosis or prediction of preeclampsia or complications, 2,4 the majority identifying advanced disease with established end-organ damage.
have advantages over blood pressure and urinary protein, which are the consequences of established disease. Because earlier gestation of preeclampsia onset is associated with greater maternal and perinatal risks, 1 and the difference in PlGF concentrations between normal and preeclamptic pregnancies is most marked before 35 weeks, PlGF has potential to aid the diagnosis of hypertensive disorders of pregnancy at gestations critical to clinical outcome. The most clinically relevant test for health professionals would identify women with preeclampsia associated with deteriorating disease requiring iatrogenic delivery. Because women with suspected hypertensive disease are routinely monitored every 2 weeks, a test should be applicable for a subsequent 14-day window to impact management strategies.
The primary aim of this study was to evaluate the diagnostic accuracy of plasma PlGF concentrations in women presenting with suspected preeclampsia between 20 and 35 weeks' gestation (up to 40 +6 weeks as a secondary analysis) in determining the need for delivery for preeclampsia within 14 days of testing (preeclampsia-D14).
Methods
This prospective observational study was undertaken between January 2011 and February 2012 in 7 consultant-led maternity units in the once. Written informed consent was obtained, and baseline demographic and pregnancy-specific information was entered onto the study database (finalized before the first participant being enrolled). Fifteen milliliters of blood (additional to routine blood samples) were drawn into ethylenediamine tetra-acetic acid and transported to the laboratory within 1 hour, and plasma stored until analysis (−80°C). Pregnancy outcome details for mother and infant were obtained from case note and electronic database review. Participants were recruited until sufficient numbers in each prespecified gestational age range had been reached. The study was approved by East London Research Ethics Committee (ref. 10/H0701/117). Definitions and outcomes were prespecified in the study protocol. The primary analysis was of diagnostic accuracy of low plasma PlGF (<5th centile for gestational age) to predict the need to deliver for preeclampsia within 14 days of testing in women with suspected preeclampsia before 35 weeks' gestation. The prespecified secondary analyses included women presenting later (35-36 +6 ; ≥37 weeks), or by using a lower threshold (<12 pg/mL). All hypertensive disorders of pregnancy, including superimposed and severe preeclampsia, were defined according to the American College of Obstetricians and Gynaecologists practice bulletin; superimposed preeclampsia was defined as new-onset proteinuria in women with hypertension before 20 weeks, a sudden increase in proteinuria if already present in early gestation, a sudden increase in hypertension, or the development of hemolysis, elevated liver enzymes, and low platelet count (HELLP) syndrome. 10 Atypical preeclampsia was defined by the International and Australasian Societies for the Study of Hypertension in Pregnancy 11 as gestational hypertension without proteinuria but with other multiorgan involvement or fetal growth restriction (<10th customized birthweight centile). The latter 12 was calculated by using the Gestation Related Optimal Weight method by freely available software. 13 The final adjudicated diagnosis of pregnancy outcome was the reference standard for evaluating PlGF test accuracy. This was determined by 2 independent senior physicians requiring documentation of end points required to fulfill the diagnostic criteria; disagreement was resolved by a third adjudicator. All adjudicators were masked to PlGF values when assigning a final diagnosis; PlGF measurements were not revealed until all subject adjudication was complete. Ten percent of database records were verified against source data by an independent assessor.
Plasma samples were tested, using the Triage PlGF Test (Alere, San Diego, CA), at each study center according to the manufacturer's instructions. All meters were programmed for study duration to produce a masked result, determining satisfactory test completion only, without revealing the value. All laboratory staff were unaware of clinical outcomes. To determine assay reproducibility, replicate samples were also tested at a central laboratory. The assay uses fluorescently labeled recombinant murine monoclonal antibodies and detects PlGF specifically and quantitatively, in the range of 12 to 3000 pg/mL, in ≈15 minutes. The Total Precision (coefficient of variation) on plasma controls at concentrations of 85 and 1300 pg/mL is 12.8% and 13.2%, respectively, based on the manufacturer's package insert generated before the study.
As prespecified, women were classified according to the gestation of the test, <35, 35 to 36 +6 , and ≥37 weeks; the test result, normal (≥5th centile for gestation), low (<5th centile), and very low (<12 pg/ mL); and the principal outcome, preeclampsia-D14. A positive test was PlGF concentration <5th centile for gestational age for normal controls (calculated from 247 women with normal pregnancies contributing 1366 samples between 20 and 40 weeks' gestation). 14 Test performance was evaluated as sensitivity, specificity, positive and negative predictive values, positive and negative likelihood ratios, and receiver operating characteristics (ROC) areas. Kaplan-Meier survival curves of gestational age at delivery were produced, treating data as left-censored before the gestation at which the test was conducted or at 24 weeks (to avoid very low numbers at gestation of the first delivery). The curves represent the probability of delivery conditional on no delivery before the gestation of the earliest test. Median and interquartile ranges for the time from PlGF test to delivery were calculated. Logistic regression was used to consider whether the utility of PlGF was limited to women delivering small for gestational age infants. Comparison of PlGF with other standard tests for preeclampsia (systolic and diastolic blood pressure, proteinuria, uric acid, alanine transaminase) was performed for the primary outcome by using unadjusted PlGF concentrations. The 4 tests (excluding proteinuria, which amounts to confirmation of diagnosis) were combined into a single predictor by using logistic regression, and ROC areas were compared for the prediction of the primary end point. For implementation to clinical practice in women <37 weeks' gestation, an exploratory analysis was conducted with the aim of identifying a single threshold (independent of gestation) with test performance statistics similar to 5th centile, while retaining the properties of a clinically relevant test (high sensitivity, high negative predictive value). We evaluated test biochemical reproducibility by analyzing all samples a second time in 1 central laboratory. The required sample sizes were calculated for accurate estimation of the sensitivity (within 10%) and specificity (within 6%) of PlGF in determining the primary end point. We assumed a sensitivity of 0.90, specificity 0.90, and 95% confidence intervals (2-tailed), requiring 62 preeclampsia cases and 150 nonpreeclamptic women. Because adjudication of the final diagnosis (after delivery) lagged behind enrollment, 287 women were recruited before 35 weeks' gestation before enrollment was stopped. Statistical analysis was performed in the statistical package Stata (version 11.2), College Station, TX. The study is reported in accordance with STAndards for the Reporting of Diagnostic accuracy studies (STARD) guidelines.
Results
Between January 2011 and February 2012, 649 women were recruited (Figures 1 and 2) . We recruited all those who were approached, eligible, and consented but did not document women who declined to take part. Of consented women, 24 did not have a valid baseline sample (17) or were lost to follow-up (7) . The characteristics of the remaining 625 women are shown in Table 1 , maternal and infant outcomes are in Table 2 , details of adverse maternal and perinatal outcomes Table 3 .
The diagnostic accuracy of PlGF for predicting preeclampsia-D14 (primary outcome) is shown in Table 4 , with the use of prespecified thresholds of <5th centile and <12 pg/mL. All values, including outliers, were included. Low PlGF <5th centile had high sensitivities and negative predictive values for women tested before 35 weeks, declining at later gestations. For implementation into clinical practice for women presenting before 37 weeks' gestation, an exploratory analysis determined that a PlGF threshold of <100 pg/mL predicted preeclampsia-D14 or before 37 weeks' gestation (whichever was sooner) with sensitivity and negative predictive values similar to diagnostic accuracy estimates obtained by using a <5th centile cutoff ( For women presenting before 35 weeks' gestation, there were 3 cases with false-negative results (≥5th centile), all with an additional indication for early delivery; 4 cases with PlGF <12 pg/mL were delivered after 37 weeks with severe preeclampsia, 3 of whom delivered infants ≤5th customized birthweight centile, suggesting placental disease (Table 5 ). PlGF was <5th centile in all cases and <12 pg/mL in 4 of the 7 cases of antepartum fetal death (occurring after enrollment; Table 5 ). PlGF <5th centile predicted intrauterine fetal death with sensitivity 1.00 (95% confidence interval, 0.71-1.00); specificity 0.48 (0.44-0.52); positive predictive value 0.03 (0.02-0.05); negative predictive value 1.00 (0.99-1.00). In 5 cases, testing at enrollment predated Doppler ultrasound abnormalities by 7 to 39 days and predated the stillbirth by 10 to 53 days.
The area under the ROC curve for low PlGF in predicting preeclampsia-D14 was greater than all other commonly used tests, either singly or in combination (P<0.001 for all comparisons; Figure 3 ). The addition of blood pressure or other blood tests currently used did not increase the ROC area further in comparison with PlGF alone. PlGF was a consistently good predictor of preeclampsia-D14 in women with and without ≥ 1+ dipstick proteinuria. The times (in days) to delivery for the 3 PlGF groups are presented for women with all diagnoses and for preeclampsia cases (Figure 4 ). For test reproducibility, 595 paired samples were measured both at the study site and at the central laboratory (30 results were unevaluable owing to error codes, or mismatched sample identifications). Four hundred twenty-five were in-range (between 12 and 3000 pg/mL) on both evaluations and had a Pearson correlation coefficient of 0.950. For all 595 PlGF test pairs (including out-of-range values), the Spearman (rank) correlation coefficient was 0.948. A Bland-Altman plot is presented in Figure II in the online-only Data Supplement. Of women evaluated, 85.4% would receive the same classification in both laboratories; 11.1% moved between low and very low (in either direction), and a further 3.5% moved between low and normal. No woman moved between very low and normal. The sensitivity and specificity of the test in predicting the primary outcome were changed by <1% when 29 twin pregnancies were excluded. There were no adverse events associated with the collection of the blood necessary for performing PlGF testing.
Table 5. False Negatives, Cases With Very Low PlGF and Term Delivery, and Antepartum Deaths in Women Presenting <35 Weeks' Gestation

Discussion
This study suggests that PlGF testing presents a realistic and innovative adjunct to the management of women with suspected preeclampsia, especially those presenting preterm. Low PlGF concentration (<5th centile or ≤100 pg/mL) has high sensitivity and negative predictive value in determining which women presenting with suspected disease at <35 weeks' gestation are likely to need delivery for preeclampsia within 14 days. A previous review has highlighted the need for a test with high sensitivity in this setting, because there is greater preference for minimizing false negatives when considering overall benefits and harms and in ensuring appropriate resource use. 15 Time to delivery is markedly different for women with very low, low, and normal PlGF values, facilitating stratified management strategies with appropriate surveillance. PlGF was more predictive of the need for delivery than other commonly used signs and tests, either singly or in combination, in current clinical practice. Sensitivity and negative predictive values were also high for delivery of an small for gestational age infant <1st centile; this indicator is most likely to equate to fetal growth restriction of placental origin and to be associated with adverse perinatal outcomes. Although diagnostic accuracy is greatest for women presenting before 35 weeks' gestation, the test may still benefit those presenting up to 37 weeks' gestation (using a threshold of <100 pg/mL) for whom stratified surveillance is also advantageous and the risks/benefits of delivery remain uncertain.
The strengths of this study include the use of multiple centers encompassing a wide demographic and ethnic profile and a pragmatic approach to enrollment with minimal exclusion criteria, enabling generalizability. The main research question was chosen to be clinically relevant, with the use of a primary outcome where delivery was indicated for the mother or infant, despite being preterm. Final diagnoses were independently adjudicated by 2 senior clinicians following database record review with the use of strict criteria. PlGF concentrations were not revealed until all diagnoses had been adjudicated, so that the test result could not influence decisions for delivery. Laboratory staff were also unaware of the diagnosis. The analysis followed prespecified methods and outcomes, with subsequent transparent evaluation of a single PlGF threshold (rather than using a variable 5th centile threshold dependent on gestational age) to enable easier adoption into clinical practice.
The optimal choice of primary outcome was difficult. When the study was planned, there was no validated composite measure of adverse outcome for women with preeclampsia. The fullPIERS model subsequently published used a composite outcome determined by iterative Delphi consensus 16 ; components of this composite (other than blood transfusion) are reported in our study. Maternal plasma PlGF normally declines in the latter part of the third trimester, reducing test performance at >35 weeks' gestation; an ideal test would maintain separation between preeclamptic cases and other women, which is probably unachievable by using a single biomarker at all gestations. More accurate determination of very low PlGF values (less than the current limit of detection of 12 pg/mL) could be useful; however, the high clinical sensitivity reported in this study relates to the prespecified threshold of <5th centile (low PlGF, or PlGF <100 pg/m:) rather than very low PlGF. This is the largest, and the first prospective multicenter, study to evaluate PlGF in women with suspected preeclampsia. Other studies have evaluated PlGF and other factors including soluble Flt-1 (sFlt-1; soluble fms-like tyrosine kinase-1), a trophoblast derived antiangiogenic factor that is increased in plasma from preeclamptic women. A case-control study 7 and a small prospective observational study 17 using the Triage assay reported promising test performance. A more recent study using a different assay for sflt-1/PlGF ratio (Elecsys platform, Roche, Penzburg, Germany) found considerably lower sensitivity (0.73) and negative predictive value (0.87) at high specificity (0.94) in predicting maternal adverse outcome in women presenting at <34 weeks' gestation, 18 a level of sensitivity that is unlikely to be useful in clinical practice. Direct comparison of assays in 128 pregnant women (44 with preeclampsia) confirmed higher sensitivity of the Triage test than the sflt-1/ PlGF ratio (Elecsys) in diagnosing early-onset preeclampsia, 19 which may relate to different target epitopes of PlGF used in the Triage test. Other studies have not reported sensitivity and specificity (recommended measures of diagnostic accuracy), making direct comparison difficult, 20, 21 have compared assays in women with established disease 22 or have tested at a fixed time point rather than at presentation. 23, 24 Suspected preeclampsia is the most frequent clinical presentation to obstetric day care assessment units, and those with early-onset disease are at the greatest risk. Current signs and tests do not perform well in predicting need for delivery or adverse outcomes. [25] [26] [27] We hypothesize that adding PlGF measurement to current clinical assessment of women with suspected preeclampsia before 37 (and particularly before 35) weeks' gestation could improve risk stratification, achieve an earlier diagnosis based on underlying pathophysiology, enable individualized management of women with the disease, with the potential to reduce associated maternal morbidity and unnecessary health service usage. There may be a double benefit: targeting of resources to those at highest risk, while minimizing excessive assessment and intervention in women at lower risk. One decision-analytic modeling analysis has estimated $1400 cost saving associated with the introduction of PlGF testing (based on a sensitivity of 0.82) for the management of pregnant women in a UK setting. 28 Cost savings may be greater when the Triage platform has been adapted to test whole blood at the point-of-care. We would propose that further assessment of PlGF should be undertaken in the context of a randomized, controlled trial, as recommended for all new diagnostic tests, to measure the impact on the health of mother and infant through changing diagnostic/ treatment decisions, time to treatment, and potential harms, as well. 29 Hypertensive disorders of pregnancy remain a challenge worldwide, as indicated by the recent Global Burden of Disease Study 30 ;improved detection and management have also been strongly recommended for reduction of stillbirths. 31 Although current strategies focus on blood pressure measurement and assessment of end-organ damage, this study provides evidence for the recently proposed concept that better diagnosis results from measuring secondary rather than tertiary features of preeclampsia. 32
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